DAPAGLIFLOZIN EXPERIENCE AS ADDED TO TRIPLE THERAPY FOR THE TREATMENT OF UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS IN A CENTRE OF HIGH COMPLEXITY, CALI-COLOMBIA

Session Name
NEW MEDICATIONS FOR TREATMENT OF DIABETES
Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Date
20.02.2020, Thursday
Session Time
09:30 - 15:30
Channel
E-Poster Area
Lecture Time
09:32 - 09:33
Presenter
  • Nathalia Buitrago gómez, Colombia
Authors
  • Nathalia Buitrago gómez, Colombia
  • Vanessa Bedoya, Colombia
  • Alín Abreu lomba, Colombia
  • Jenny P. Muñoz, Colombia
  • Luis M. Osorio, Colombia
  • Carlos A. Salgado, Colombia
  • Reinaldo Carvajal ortiz, Colombia

Abstract

Background and Aims

Less than 40% of people with type 2 diabetes mellitus (T2DM) present HbA1c levels <7%. Dapagliflozin has demonstrated an impact on cardiovascular outcomes, weight loss, and a reduction in blood pressure. Evidence that allows evaluating combination therapies is still scarce. We aim to evaluate the effectiveness of the use of dapagliflozin as an intensification therapy in triple therapy for the treatment of patients with uncontrolled T2DM.

Methods

A quasi-experimental study was conducted in 123 adult patients aged over 18 years, diagnosed with uncontrolled type 2 diabetes mellitus, who received dapagliflozin added to their dual base treatment: metformin plus glibenclamide (n = 32), metformin plus saxagliptin (n = 29), metformin plus exenatide (n = 28) and metformin plus insulin (n = 34).

Results

All 123 patients completed the 52-week follow-up. The mean age, according to the study group, fluctuated between 52.8 ± 9.2 and 57.4 ± 5.9 years. 52.8% were women. The Hispanic population represented the largest number of patients in all groups. The mean reduction in the change in differences in HbA1cvalues, fasting plasma glucose (FPG), weight and blood pressure during the study period showed a linear trend of decrease from the start at 52 weeks statistically significant ( p-value = <0.001).

Conclusions

The addition of dapagliflozin as an intensification alternative to the dual therapy for uncontrolled type 2 diabetic patients, consistently improved FPG and HbA1c, body weight and blood pressure, with statistically significant results.

Hide